AI Article Synopsis
- COVID-19, a viral pneumonia first identified in Wuhan in December 2019, has globally impacted health despite a relatively low case fatality rate, leading to significant deaths due to infection.
- Severe COVID-19 patients often experience cytokine storms, a critical condition contributing to mortality, highlighting the need for effective treatments targeting this response.
- Tocilizumab, an IL-6 receptor blocker, has emerged as a promising therapeutic option by inhibiting the IL-6 signaling pathway, thereby potentially improving outcomes for patients suffering from severe forms of the disease.
Article Abstract
Since December 2019, a viral pneumonia, named coronavirus disease 2019 (COVID-19), from Wuhan, China, has swept the world. Although the case fatality rate is not high, the number of people infected is large and there is still a large number of patients dying. With the collation and publication of more and more clinical data, a large number of data suggest that there are mild or severe cytokine storms in severe patients, which is an important cause of death. Therefore, treatment of the cytokine storm has become an important part of rescuing severe COVID-19 patients. Interleukin-6 (IL-6) plays an important role in cytokine release syndrome. If it is possible to block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe COVID-19 patients. Tocilizumab is an IL-6 receptor (IL-6R) blocker that can effectively block the IL-6 signal transduction pathway and thus is likely to become an effective drug for patients with severe COVID-19.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118634 | PMC |
| http://dx.doi.org/10.1016/j.ijantimicag.2020.105954 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!